Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Lowered by Wall Street Zen

Intellia Therapeutics (NASDAQ:NTLA) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Several other equities research analysts also recently issued reports on NTLA. Robert W. Baird boosted their price objective on shares of Intellia Therapeutics from $7.00 to $13.00 and gave the stock a “neutral” rating in a research note on Monday, April 27th. Wells Fargo & Company boosted their price objective on shares of Intellia Therapeutics from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research note on Tuesday, March 3rd. Truist Financial upgraded shares of Intellia Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. reiterated a “buy” rating on shares of Intellia Therapeutics in a research note on Tuesday, March 3rd. Finally, KeyCorp set a $25.00 price objective on shares of Intellia Therapeutics in a research note on Wednesday, January 28th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $20.25.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock opened at $13.67 on Friday. Intellia Therapeutics has a 1 year low of $6.83 and a 1 year high of $28.25. The firm has a 50 day moving average price of $13.63 and a 200 day moving average price of $11.97. The company has a market cap of $1.91 billion, a price-to-earnings ratio of -3.86 and a beta of 1.93.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. The company had revenue of $15.05 million during the quarter, compared to the consensus estimate of $13.81 million. During the same period in the previous year, the firm earned ($1.10) earnings per share. Sell-side analysts predict that Intellia Therapeutics will post -3.35 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Comerica Bank lifted its position in shares of Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after purchasing an additional 901 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of Intellia Therapeutics during the second quarter worth $26,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Intellia Therapeutics during the third quarter worth $30,000. Advisory Services Network LLC acquired a new position in shares of Intellia Therapeutics during the third quarter worth $33,000. Finally, Spire Wealth Management acquired a new position in shares of Intellia Therapeutics during the fourth quarter worth $37,000. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics News Roundup

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Intellia Therapeutics and reaffirmed a $25 price objective, signaling continued upside confidence. Intellia Therapeutics Price Target Cut to $25.00 by Analysts at HC Wainwright
• Positive Sentiment: The firm raised its FY2026 EPS estimate to a loss of $3.00 per share from a larger loss previously expected, suggesting some improvement in the earnings outlook. Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA)
• Positive Sentiment: HC Wainwright also lifted near-term estimates for Q2 2026 and Q3 2026, indicating analysts now expect slightly better operating performance than before. Intellia Therapeutics, Inc. First-Quarter Results Just Came Out: Here’s What Analysts Are Forecasting For This Year
• Neutral Sentiment: Other brokerage notes from Wells Fargo and Wedbush reportedly remained at Hold, suggesting the stock still has mixed analyst support.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.